SAVARA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.33 USD | +0.70% |
|
-10.35% | -7.87% |
| May. 21 | Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating | MT |
| May. 09 | Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 4.9M | Capitalization | 594M |
|---|---|---|---|---|---|
| Net income 2024 * | -78M | Net income 2025 * | -65M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 121 x |
| P/E ratio 2024 * |
-10.8
x | P/E ratio 2025 * |
-10.5
x | Employees | 37 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Savara Inc.
More recommendations
More press releases
| 1 day | +0.70% | ||
| 1 week | -9.98% | ||
| Current month | -5.46% | ||
| 1 month | -9.98% | ||
| 3 months | -9.79% | ||
| 6 months | +16.09% | ||
| Current year | -7.87% |
1 week
4.15
4.84
1 month
4.065.31
Current year
4.065.70
1 year
2.465.70
3 years
1.025.70
5 years
0.6911.53
10 years
0.6917.19
| Managers | Title | Age | Since |
|---|---|---|---|
Matthew Pauls
CEO | Chief Executive Officer | 53 | 17-04-26 |
David Lowrance
DFI | Director of Finance/CFO | 56 | 17-04-26 |
Robert Lutz
COO | Chief Operating Officer | 55 | 23-02-12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Ramsay
BRD | Director/Board Member | 59 | 17-04-26 |
Richard Hawkins
BRD | Director/Board Member | 75 | 10-09-30 |
Nevan Elam
BRD | Director/Board Member | 56 | 09-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +4.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 4.33 | +0.70% | 779,740 |
| 24-05-21 | 4.3 | +3.12% | 888,162 |
| 24-05-20 | 4.17 | -6.92% | 1,353,270 |
| 24-05-17 | 4.48 | -5.08% | 827,427 |
| 24-05-16 | 4.72 | -2.28% | 457,624 |
Delayed Quote Nasdaq, May 22, 2024 at 04:00 pm EDT
More quotes
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Companyâs lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Calendar
2024-06-06
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.3
USD
Average target price
9
USD
Spread / Average Target
+109.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.87% | 594M | |
| +9.99% | 114B | |
| +12.01% | 107B | |
| -3.07% | 22.22B | |
| -0.67% | 21.28B | |
| -4.64% | 18.8B | |
| -6.90% | 17.51B | |
| -39.36% | 17.17B | |
| +5.82% | 14.14B | |
| +33.05% | 12.2B |
- Stock Market
- Equities
- SVRA Stock
